Immune responses to adeno-associated virus and its recombinant vectors

被引:0
|
作者
J Y Sun
V Anand-Jawa
S Chatterjee
K K Wong
机构
[1] Division of Hematology and Stem Cell Transplantation,Division of Virology
[2] City of Hope,undefined
来源
Gene Therapy | 2003年 / 10卷
关键词
recombinant adeno-associated virus (rAAV) vectors; immunogenicity; genetic vaccination;
D O I
暂无
中图分类号
学科分类号
摘要
Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV-encoded transgenes, raising the potential for their use in vaccine development. In this review, we summarize current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.
引用
收藏
页码:964 / 976
页数:12
相关论文
共 50 条
  • [1] Immune responses to adeno-associated virus and its recombinant vectors
    Sun, JY
    Anand-Jawa, V
    Chatterjee, S
    Wong, KK
    GENE THERAPY, 2003, 10 (11) : 964 - 976
  • [2] Immune responses to adeno-associated virus vectors
    Zaiss, AK
    Muruve, DA
    CURRENT GENE THERAPY, 2005, 5 (03) : 323 - 331
  • [3] Innate immune responses to adeno-associated virus vectors
    Zaiss, AK
    White, LR
    Wong, NCW
    Bartlett, JS
    Muruve, DA
    MOLECULAR THERAPY, 2004, 9 : S283 - S284
  • [4] Immune responses to recombinant adeno-associated virus vectors: Putting preclinical findings into perspective
    Flotte, TR
    HUMAN GENE THERAPY, 2004, 15 (07) : 716 - 717
  • [5] Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
    Ronzitti, Giuseppe
    Gross, David-Alexandre
    Mingozzi, Federico
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [6] Biosafety of Recombinant Adeno-associated Virus Vectors
    Dismuke, David J.
    Tenenbaum, Liliane
    Samulski, R. Jude
    CURRENT GENE THERAPY, 2013, 13 (06) : 434 - 452
  • [7] Production of recombinant adeno-associated virus vectors
    Zolotukhin, S
    HUMAN GENE THERAPY, 2005, 16 (05) : 551 - 557
  • [8] Targeting of recombinant adeno-associated virus vectors
    Hallek, M
    Büning, H
    Ried, M
    Perab, L
    Kofler, D
    Gerner, F
    Wendtner, CM
    Leike, K
    Huttner, N
    Hutter, M
    CANCER GENE THERAPY, 2001, 8 (09) : 688 - 688
  • [9] Humoral immune responses to Adeno-associated Virus vectors in mice.
    Chirmule, N
    Xiao, WD
    Ehlen-Haecker, S
    Wilson, JM
    FASEB JOURNAL, 1999, 13 (04): : A193 - A193
  • [10] Modifying immune responses to adeno-associated virus vectors by capsid engineering
    Bentler, Martin
    Hardet, Romain
    Ertelt, Moritz
    Rudolf, Daniela
    Kaniowska, Dorota
    Schneider, Andreas
    Vondran, Florian W. R.
    Schoeder, Clara T.
    Delphin, Marion
    Lucifora, Julie
    Ott, Michael
    Hacker, Ulrich T.
    Adriouch, Sahil
    Buening, Hildegard
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 576 - 592